You are here

P&T May 2014

Features

But in Some Instances, the Industry Is Pushing Back
The Food and Drug Administration, concerned about the quality of the generic drugs that represent 84 percent of U.S. prescriptions, is looking more closely at foreign manufacturing plants and weighing other changes in the generic approval process.

Health care professionals’ use of mobile devices is transforming clinical practice. Numerous medical software applications can now help with tasks ranging from information and time management to clinical decision-making at the point of care.

Biomarkers and Combination Therapies May Lead To Disease-Modifying Treatments, Experts Say
Developing a disease-modifying treatment for Alzheimer’s disease has stymied researchers. A collaborative re-examination of premises that guided disappointing earlier trials is under way, with talk of new targets and combination therapies.

Departments

Medication Errors
Actions on patient safety speak louder than words.
Prescription: Washington
DEA’s hydrocodone combination plan divides pharmacists.

FDA approvals, drug indications, and updates

Droxidopa (Northera) for neurogenic orthostatic hypotension, elosulfase alfa (Vimizim) for Morquio A syndrome, and sodium hyaluronate in phosphate-buffered saline (Monovisc) to address knee osteoarthritis

Drug Forecast

Sofosbuvir: A new oral oncedaily agent for the treatment of hepatitis C virus infection

Meeting Highlights

Attendees at the American Academy of Dermatology meeting found heightened interest in psoriasis treatments.

Meeting Highlights

The American College of Cardiology meeting included sessions on heparin versus bivalirudin and a controversy over renal denervation.